Here's Why I Bought Shares of This Genetics Company

We recently learned that home DNA-testing company 23andMe will be going public through a merger with special purpose acquisition company (SPAC) VG Acquisition Corp (NYSE: VGAC). In this Fool Live video clip, recorded on March 15, Fool.com contributor Matt Frankel, CFP, explains to Industry Focus host Jason Moser why he owns shares of this high-potential genetics company in his personal stock portfolio, specifically in the context of their pharmaceutical development potential. 

Continue reading

Source Fool.com